• MAHMOUD H. TEAIMA Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
  • KHALED M. ABDEL-HALEEM Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Giza, Egypt
  • MOHAD OSAMA Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Giza, Egypt
  • MOHAMED A. EL-NABARAWI Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
  • SAHAR M. FAYEZ Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Giza, Egypt



Bi-laminated; Oral disintegrating film; Pitavastatin calcium; Lornoxicam; Liquid Chromatography-Mass Spectrometry.


Objective: Pitavastatin calcium (PT) is an innovative drug of statins that enhances HDL-C and lowers LDL-C. However, myalgia has been reported in hyperlipidemic patients receiving statins. Therefore, co-administration of statins with NSAIDs such as Lornoxicam (LN) could be a solution to the former problem. Accordingly, this study aimed to formulate a bi-laminated oral disintegrating film (ODF) comprising PT in one layer and LN in the second one.

Methods: For the formulation and optimization of PT-ODFs, a 31.21 full factorial design was carried out, where the impact of polymer type and concentration on disintegration time (DT) and % PT released after 10 min (Q10) was studied. PT-ODFs were prepared via the solvent casting method and then evaluated. One PT-ODF was chosen to represent the optimum formula according to the criteria of scoring the fastest DT and the highest Q10. The optimized PT-ODF was merged with the second film layer containing LN, forming a bi-laminated ODF named S1 that underwent an in-vivo pharmacokinetic study compared to the commercially available tablets for PT (Lipidalon®) and LN (Lornoxicam®) using rats as an animal model. LC-MS/MS was used to analyze plasma drug concentrations.

Results: All PT-ODFs showed acceptable outcomes. F1 scored the fastest DT (18.6±1.5 s) and the highest Q10 (91.3±3.0 %). S1 successfully recorded a maximum plasma concentration (Cmax) of 2.04 and 2.24 folds increase for PT and LN, correspondingly, compared to commercially available tablets.

Conclusion: Merging PT and LN into bi-laminated ODF was promising for the fast delivery of both drugs with enhanced bioavailability.


Download data is not yet available.


Kumar P, Mangla B, Singh S. Pitavastatin: a potent drug. Int J Pharm Res Health Sci. 2018; 6:2070-74. doi: 10.21276/ijprhs.2018.01.01.

Niranjani S, Venkatachalam K. Method development and validation of pitavastatin calcium and its degradation behavior under varied stress conditions by UV spectrophotometric methods. J Pharm Sci. 2019; 18:159–69. doi: 10.3329/dujps.v18i2.43258.

Taylor BA, Thompson PD. Statin-associated muscle disease: advances in diagnosis and management. Neurotherapeutics. 2018; 15:1006–17. doi: 10.1007/s13311-018-0670-z.

Zhou Z, Albarqouni L, Breslin M, Curtis AJ, Nelson M. Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ. 2017; 7:1–7. doi: 10.1136/bmjopen-2017-017587.

Teaima MH, Abdel-Haleem KM, Osama R, El-Nabarawi MA, Elnahas OS. A promising single oral disintegrating tablet for co-delivery of pitavastatin calcium and lornoxicam using co-processed excipients: Formulation, characterization and pharmacokinetic study. Drug Des Devel Ther. 2021; 15:4229–42. doi:10.2147/DDDT.S332729.

Hatt KM, Vijapura A, Maitin IB, Cruz E. Safety considerations in prescription of NSAIDs for musculoskeletal pain: PM R. 2018; 10:1404–11. doi: 10.1016/j.pmrj.2018.06.011.

Helmy HS, El-Sahar AE, Sayed RH, Shamma RN, Salama AH, Elbaz EM. Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis. Int J Nanomedicine. 2017; 12:7015–23. doi: 10.2147/IJN.S147738.

El-Mahmoudy A. Pharmacokinetics of lornoxicam in rabbits after single intravenous bolus and intramuscular administrations. Int J Pharmacol Toxicol. 2016; 4:66-73. doi: 10.14419/ijpt.v4i1.5998.

El-Nabarawi MA, Elshafeey AH, Mahmoud DM, El Sisi AM. Fabrication, optimization, and in-vitro/in-vivo evaluation of diclofenac epolamine flash tablet. Drug Deliv Transl Res. 2020; 10:1314-26. doi: 10.1007/s13346-020-00709-4.

Gupta P, Bisht A, Rao NGR. Fast dissolving oral films: a comprehensive review. World J Pharm Med Res. 2019; 5:116–27.

Zayed GM, El Rasoul SA, Ibrahim MA, Saddik MS, Alshora DH. In-Vitro and in-vivo characterization of domperidone-loaded fast dissolving buccal films. Saudi Pharm J. 2020; 28:266–73. doi: 10.1016/j.jsps.2020.01.005.

Tayel SA, El Nabarawi MA, Amin MM, Abou Ghaly MH. Sumatriptan succinate sublingual fast dissolving thin films: Formulation and in-vitro/in-vivo evaluation. Pharm Dev Technol. 2016; 21:328–37. doi: 10.3109/10837450.2014.1003655.

Kumar SV, Gavaskar B, Sharan G, Rao YM. Overview on fast dissolving films. Int J Pharm Pharm Sci. 2010; 2:29–33.

Liew KB, Peh KK, Tan YTF. Orally disintegrating dosage forms: breakthrough solution for non-compliance. Int J Pharm Pharm Sci. 2013; 5:4–8.

El-Nabarawi MA, Makky AM, El-Setouhy DA, Abd Elmonem RA, Jasti BA. Development and characterization of ketorolac tromethamine (KT) orobuccal films. Int J Pharm Pharm Sci. 2012; 4:186–93.

Abouhussein D, El Nabarawi MA, Shalaby SH, El-Bary AA. Cetylpyridinium chloride chitosan blended mucoadhesive buccal films for treatment of pediatric oral diseases. J Drug Deliv Sci Technol. 2020; 57:1-9. doi: 10.1016/j.jddst.2020.101676.

Bala R, Sharma S. Formulation, Optimization and evaluation of fast dissolving film of aprepitant by using design of experiment. Bull Fac Pharmacy, Cairo Univ. 2018; 56:159–68. doi: 10.1016/j.bfopcu.2018.04.002.

Pallavi K, & Pallavi T. Formulation and evaluation of fast dissolving films of eletriptan hydrobromide. Int J Curr Pharm Res. 2017; 9:59-63. doi: 10.22159/ijcpr.2017v9i2.17386.

Tiwari RR, Umashankar MS, Damodharan N. Recent update on oral films: a bench to market potential. Int J App Pharm. 2018; 10:27–33. doi: 10.22159/ijap.2018v10i6.28725.

Farid M, El-Setouhy DA, El-Nabarawi MA, El-Bayomi T. Particle engineering/different film approaches for earlier absorption of meloxicam. Drug Deliv. 2016; 23:2309–17. doi: 10.3109/10717544.2014.982262.

El-Nabarawi MA. Modulation of tenoxicam release from hydrophilic matrix: modulator membrane versus rate-controlling membrane. Chem Pharm Bull. 2005; 53:1083–87. doi: 10.1248/cpb.53.1083.

Sanjay P, Vishal GN, Gowda DV, Sivadasu P. Formulation and evaluation of oral disintegrating film of atenolol. Asian J Pharm Clin Res. 2018; 11:312–15. doi: 10.22159/ajpcr.2018.v11i8.26464.

Shukla V, Manvi F V. Effect of kollidon Cl on release behavior of isoniazid and rifampicin combination dispersible tablets for oral treatment of tuberculosis. Int J Drug Dev Res. 2010; 2:892–906.

ElMeshad AN, Abdel-Haleem KM, Abdel Gawad NA, El-Nabarawi MA, Sheta NM. Core in cup ethylmorphine hydrochloride tablet for dual fast and sustained pain relief: formulation, characterization, and pharmacokinetic study. AAPS PharmSciTech. 2020; 21:1–11. doi: 10.1208/s12249-020-01759-0.

El-Nabarawi MA, Makky AM, El-Setouhy DA, Abd-Elmoniem R, Amin MG, Jasti BA. Fabrication, evaluation, and preliminary clinical study of bi-layer orobuccal devices containing ketorolac tromethamine and chlorhexidine HCL for treatment of oral inflammation. Int J Pharm Pharm Sci. 2014; 6:851–57.

Carolina VJ, Weggemans OAF, Boosman RJ, Loos KU, Frijlink HW, Woerdenbag HJ. Increased drug load and polymer compatibility of bilayered orodispersible films. Eur J Pharm Sci. 2017; 107:183–90. doi: 10.1016/j.ejps.2017.07.010.

Habib BA, Abd El-Samiae AS, El-Houssieny BM, Tag R. Formulation, characterization, optimization, and in-vivo performance of febuxostat self-nano-emulsifying system loaded sublingual films. Drug Deliv. 2021; 28:1321– 33. doi: 10.1080/10717544.2021.1927247.

Mukhtar RYA, Reid J, Reckless JPD. Pitavastatin. Int J Clin Pract. 2005; 59:239–52. doi: 10.1111/j.1368-5031.2005.00461.x.

Ansari JA, Bhandari U, Haque SE, Pillai KK. Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in wistar rats. Toxicol Mech Methods. 2012; 22:67–73. doi: 10.3109/15376516.2011.603391.

Li F, Song S, Guo Y, Zhao Q, Zhang X, Pan W, et al. Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug lornoxicam. Drug Deliv. 2015; 22:487–98. doi:10.3109/10717544.2014.885615.

Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983; 16:109–10. doi: 10.1016/0304-3959(83)90201-4.

Bae J, Johnston TA, Chaiittianan R, Sutthanut K, Jay M, Marson L. Characterization and in-vivo efficacy of a heptapeptide ODT formulation for the treatment of neurogenic bladder dysfunction. Int J Pharm. 2018; 536:397–404. doi: 10.1016/j.ijpharm.2017.11.036.

Cocchetto DM, Bjornsson TD. Methods for vascular access and collection of body fluids from the laboratory rat. J Pharm Sci. 1983; 72:465–92.

Abdelmonem RA, Abd El Galil RM, El-Setouhy DA, El-Miligi MF, El-Nabarawi MA. Dissolution enhancement and formulation of film-coated tablets of lornoxicam by phase transition method: in-vitro and in-vivo evaluation. Int J App Pharm. 2020; 12:74–85. doi: 10.22159/ijap.2020v12i3.36867.

Yin T, Liu Q, Zhao H, Zhao L, Liu H, Li M, et al. LC-MS/MS assay for pitavastatin in human plasma and subsequent application to a clinical study in healthy chinese volunteers. Asian J Pharm Sci. 2014; 9:348–55. doi: 10.1016/j.ajps.2014.07.002.

Rezaee F, Ganji F. Formulation, characterization, and optimization of captopril fast-dissolving oral films. AAPS PharmSciTech. 2018; 19:2203–12. doi: 10.1208/s12249-018-1027-y.

Satyanarayana DA, Keshavarao KP. Fast disintegrating films containing anastrozole as a dosage form for dysphagia patients. Arch Pharm Res. 2012; 35:2171–82. doi: 10.1007/s12272-012-1215-3.

Prajapati VD, Chaudhari AM, Gandhi AK, Maheriya P. Pullulan based oral thin film formulation of zolmitriptan: development and optimization using factorial design. Int J Biol Macromol. 2017; 107:2075–85. doi: 10.1016/j.ijbiomac.2017.10.082.

Zhang H, Han MG, Wang Y, Zhang J, Han ZM, Li SJ. Development of oral fast-disintegrating levothyroxine films for management of hypothyroidism in pediatrics. Trop J Pharm Res. 2015; 14:1755–62. doi: 10.4314/tjpr.v14i10.4.

Raza SN, Kar AH, Wani TU, Khan NA. Formulation and evaluation of mouth dissolving films of losartan potassium using 32 factorial design. Int J Pharm Sci Res. 2019; 10:1402–11. doi: 10.13040/IJPSR.0975-8232.10(3).1402-11.

Esim O, Ozkan CK, Kurbanoglu S, Arslan A, Tas C, Savaser A, et al. Development and in-vitro/in-vivo evaluation of dihydroergotamine mesylate loaded maltodextrin-pullulan sublingual films. Drug Dev Ind Pharm. 2019; 45:914–21. doi:10.1080/03639045.2019.1578788.

Prabhu P, Dubey A, Kamath K. Formulation and evaluation of fast-dissolving films of lisinopril. Egypt Pharm J. 2015; 14:56–64. doi: 10.4103/1687-4315.154723.

Al-Mogherah AI, Ibrahim MA, Hassan MA. Optimization and evaluation of venlafaxine hydrochloride fast dissolving oral films. Saudi Pharm J. 2020; 28:1374–82. doi: 10.1016/j.jsps.2020.09.

Alsofany JM, Hamza MY, Abdelbary AA. Fabrication of nanosuspension directly loaded fast-dissolving films for enhanced oral bioavailability of olmesartan medoxomil: In vitro characterization and pharmacokinetic evaluation in healthy human volunteers. AAPS PharmSciTech. 2018; 19:2118–32. doi: 10.1208/s12249-018-1015-2.

Ahmed IS, Shamma RN, Shoukri RA. Development and optimization of lyophilized orally disintegrating tablets using factorial design. Pharm Dev Technol. 2013; 18:935–43. doi: 10.3109/10837450.2011.619543.

Dasari N, Maruvajala V. Preparation and evaluation of fast dissolving tablets of pitavastatin by 32 full factorial design. Int J App Pharm. 2020; 12:108–14. doi: 10.22159/ijap.2020v12i1.35678.



How to Cite




Original Article(s)

Most read articles by the same author(s)